Patents Examined by Amy H. Bowman
  • Inhibitors of SRSF1 to treat neurodegenerative disorders
    Patent number: 10801027
    Abstract: The present disclosure relates to antagonists that target Serine/Arginine-Rich Splicing Factor 1 (SRSF1); expression vectors comprising SRSF1 antagonists; and the use of such antagonists in therapy for the treatment of neurodegenerative disorders and cancer and screening methods that identify agents that inhibit the expression or activity of SRSF1.
    Type: Grant
    Filed: May 30, 2017
    Date of Patent: October 13, 2020
    Assignee: University of Sheffield
    Inventors: Guillaume Hautbergue, Mimoun Azzouz, Alexander Whitworth, Pamela Shaw
  • Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof
    Patent number: 10801026
    Abstract: The present disclosure relates to a compound including a nucleic acid sequence conjugated to an anti-microRNA or a microRNA-mimic or a compound including a modified anti-microRNA sequence, compositions of such a compound, and method of treatment of a disease, and method of suppressing microRNA activity by the disclosed compound or composition.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: October 13, 2020
    Assignee: CITY OF HOPE
    Inventors: Marcin Tomasz Kortylewski, Piotr Marek Swiderski, Guido Marcucci, Bin Zhang, Ya-Huei Kuo
  • Modified oligonucleotides and methods of use
    Patent number: 10793859
    Abstract: Modified oligonucleotides comprising modifications at the 2? and/or 3? positions(s) along with methods of making and use, e.g., against HBV are disclosed.
    Type: Grant
    Filed: September 14, 2017
    Date of Patent: October 6, 2020
    Assignee: Janssen BioPharma, Inc.
    Inventors: Sergei Gryaznov, Leonid Beigelman, Antitsa Dimitrova Stoycheva, Saul Martinez Montero, Jin Hong, Rajendra K. Pandey, Vivek Kumar Rajwanshi, Lakshmipathi Pandarinathan, Yi Jin, Bharat Baral
  • Antisense compounds targeting Leucine-Rich repeat kinase 2(LRRK2) for the treatment of Parkinsons disease
    Patent number: 10787669
    Abstract: The present disclosure relates generally to compounds comprising oligonucleotides complementary to a Leucine-Rich-Repeat-Kinase (LRRK2) RNA transcript. Certain such compounds are useful for hybridizing to a LRRK2 RNA transcript, including but not limited to a LRRK2 RNA transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the LRRK2 transcript. In certain embodiments, such compounds are used to treat one or more symptoms associated with Parkinson's disease.
    Type: Grant
    Filed: June 11, 2019
    Date of Patent: September 29, 2020
    Assignees: Rosalind Franklin University of Medicine and Science, The McLean Hospital Corporation
    Inventors: Michelle L. Hastings, Ole Isacson, Joanna A. Korecka-Roet
  • Optimization method of a polynucleotide sequence
    Patent number: 10788483
    Abstract: The present invention provides for a method of optimisation of a polynucleotide sequence for use in an aptamer based assay, comprising adding additional bases to the ligand binding domain. The invention also covers methods of detecting target molecules in a sample using 5 optimised polynucleotide sequences in a suitable detection assay.
    Type: Grant
    Filed: May 15, 2015
    Date of Patent: September 29, 2020
    Assignee: Victoria Link Limited
    Inventors: Justin Hodgkiss, Omar Alsager, Shalen Kumar, Kenneth McNatty
  • Full-length and truncated anti-coagulant Dabigatran etexilate specific DNA aptamers for electrochemical and fluorescence sensing applications
    Patent number: 10788488
    Abstract: The developed long and short aptamer sequences can be used as high affinity and specificity tools to analyze the drug Dabigatran etexilate for therapeutic drug monitoring, pharmacokinetic and naturalization studies. Using the technique by performing several rounds of selection and enrichment with a randomized 60-mer DNA library, a number of specific aptamer sequences were successfully selected for Dabigatran etexilate. We evaluated the binding affinity and specificity of the generated aptamers showing dissociation constants (kd) ranging from 47-312 nM and very weak or no cross-reactivity to other analytes. Complimentary sequences labelled with a fluorophore and a quencher was used for mapping the binding region within the aptamer by monitoring the change in the fluorescence signal. A truncated sequence was used to construct a turn-on fluorescence sensor.
    Type: Grant
    Filed: November 12, 2019
    Date of Patent: September 29, 2020
    Assignee: Alfaisal University
    Inventors: Raja Chinnappan, Mohammed Zourob, Shimaa Eissa, Maher M Aljohani
  • Compositions and methods for treating cancer by inhibiting PIWIL4
    Patent number: 10787666
    Abstract: Provided methods for diagnosing and treating cancer by reducing the biological activity and/or expression of P-element induced wimpy testis-like protein 4 (PIWIL4), and related compositions and methods.
    Type: Grant
    Filed: December 14, 2016
    Date of Patent: September 29, 2020
    Assignee: ShanghaiTech University
    Inventors: Haifan Lin, Zifeng Wang, Sanhong Liu, Shuo Shi
  • Methods and compositions for cellular immunotherapy
    Patent number: 10780119
    Abstract: The present disclosure relates to genetically modified T cells comprising a transgene encoding an engineered antigen specific receptor, wherein expression of an endogenous gene selected from MNK1, MNK2, or both are inhibited in the genetically modified T cell in order to enhance central memory T cell subsets in cellular immunotherapy compositions.
    Type: Grant
    Filed: May 24, 2018
    Date of Patent: September 22, 2020
    Assignee: eFFECTOR Therapeutics Inc.
    Inventors: Kevin R. Webster, Rajesh Sharma, Gary Chiang
  • Agent for inducing cell death, agent for suppressing cell proliferation, and pharmaceutical composition used for treatment of disease resulting from abnormal cell proliferation
    Patent number: 10780107
    Abstract: This invention provides an agent and a composition that induces cancer cell death and suppresses cancer cell proliferation. The agent and the composition comprises, as an active ingredient, a drug for suppressing GST-? and MRPL17 or comprises, as active ingredients, a drug for suppressing GST-? and a drug for suppressing MRPL17.
    Type: Grant
    Filed: June 23, 2017
    Date of Patent: September 22, 2020
    Assignee: NITTO DENKO CORPORATION
    Inventors: Hiroyuki Tanaka, Kenjirou Minomi
  • miRNA-based methods for detecting and monitoring aging
    Patent number: 10781487
    Abstract: The present invention is directed to methods for detection, treatment monitoring, and slowing of aging by quantifying miRNAs in bodily fluids.
    Type: Grant
    Filed: July 24, 2018
    Date of Patent: September 22, 2020
    Assignee: DIAMIR, LLC
    Inventors: Kira S. Sheinerman, Vladimir G. Tsivinsky, Samuil R. Umansky
  • Treatment for glaucoma and other eye diseases
    Patent number: 10774328
    Abstract: The present invention includes a composition and method for the treatment of an eye disease comprising a therapeutically effective amount of an autophagy stimulator that treats or slows the progression of the eye disease by enhancing or stimulating autophagy or correcting an autophagy deficiency.
    Type: Grant
    Filed: July 11, 2017
    Date of Patent: September 15, 2020
    Assignee: UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER AT FORT WORTH
    Inventor: Gulab Zode
  • Aptasensor and method of detecting target material
    Patent number: 10775367
    Abstract: A method detects a target material in a sample, and includes: providing an aptasensor having a first aptamer capable of binding with hemin; a second aptamer capable of binding with the target material; and a nucleotide linker connecting the first aptamer and the second aptamer, adding hemin to the sample, contacting the aptasensor with the sample including hemin to bind the first aptamer with hemin and the second aptamer with the target material; adding a substrate for 1,1?-oxalyldiimidazole (ODI) chemiluminescence (CL), and measuring intensity of CL.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: September 15, 2020
    Assignee: JI Hoon LEE
    Inventor: Ji Hoon Lee
  • Compositions and methods of using piRNAS in cancer diagnostics and therapeutics
    Patent number: 10767178
    Abstract: Aberrantly expressed piRNAs, genetically associated piRNAs and their relationship with cancer risk and severity are provided. Compositions and methods of using piRNA for treating cancer are provided. Methods of diagnosing subjects and determining the efficacy of active agents for treating cancer are also provided. Methods of correlating variant piRNA to cancer are also disclosed.
    Type: Grant
    Filed: February 27, 2017
    Date of Patent: September 8, 2020
    Assignee: YALE UNIVERSITY
    Inventor: Yong Zhu
  • Liposomes for modulating Wiskott-Aldrich syndrome protein
    Patent number: 10765631
    Abstract: Embodiments of the invention relate to liposomes comprising: a lipid bilayer having an internal cavity; a therapeutic agent within the internal cavity configured to modify expression or degradation of WASp in a cell; and a targeting moiety external to the lipid bilayer configured to target an extracellular domain of a cell. Embodiments of the invention relate to methods of treatment of disease comprising administering the liposomes. Novel pharmaceutical compositions are also disclosed.
    Type: Grant
    Filed: October 29, 2018
    Date of Patent: September 8, 2020
    Assignee: BAR-ILAN UNIVERSITY
    Inventor: Mira Barda-Saad
  • Hybrid oligonucleotides and uses thereof
    Patent number: 10758558
    Abstract: Provided herein are hybrid oligonucleotides comprising a region that promotes cleavage of a nucleic acid and a region that protects a nucleic acid from exonuclease activity. Such hybrid oligonucleotides are useful for modulating the expression of genes. Related compositions and methods are also provided. In some embodiments, methods are provided for treating a disease, such as by administering a hybrid oligonucleotide.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: September 1, 2020
    Assignee: Translate Bio MA, Inc.
    Inventor: Fatih Ozsolak
  • Cancer-treating pharmaceutical composition inhibiting expression of CCND3 or PAK2 gene
    Patent number: 10760082
    Abstract: A substance inhibiting the expression of CCND3 gene or PAK2 gene, the substance containing a nucleotide such as miR-4779, may be efficiently used for preventing or treating cancer. In addition, by screening the substance that inhibits the expression of CCND3 gene or PAK2 gene, a candidate substance for preventing or treating cancer may be selected.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: September 1, 2020
    Assignee: Korea Institute of Radiological & Medical Sciences
    Inventors: Kyung Hee Koo, Hee Chung Kwon, Jie Young Song
  • Oligonucleotides for modulating gene expression and uses thereof
    Patent number: 10752900
    Abstract: The present invention regards oligonucleotides for modulating the expression of a gene, in particular for modulating a gene responsible for a pathology of genetic, tumoural or viral origin. Moreover, the present invention relates to the use of said oligonucleotides, possibly chemically modified, for the treatment and/or the diagnosis of said diseases.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: August 25, 2020
    Assignee: BIOGENERA S.P.A.
    Inventors: Roberto Tonelli, Leonardo Venturelli, Andrea Tortori, Luca Montemurro
  • Pharmaceutical composition for the prevention or treatment of nicotine addiction and withdrawal symptoms including miRNA
    Patent number: 10751360
    Abstract: Disclosed is a pharmaceutical composition for preventing or treating nicotine addiction or withdrawal symptoms. The pharmaceutical composition includes miR-137 as an active ingredient. Overexpression of miR-137 in an animal model having nicotine addiction or withdrawal symptoms results in relief, prevention or amelioration of the symptoms. Therefore, the use of miR-137 contributes to the prevention or treatment of nicotine addiction or withdrawal symptoms and is expected to be useful for developing relevant therapeutic agents.
    Type: Grant
    Filed: April 7, 2020
    Date of Patent: August 25, 2020
    Assignee: Korea Institute of Science and Technology
    Inventors: Heh-In Im, Byung Sun Kim
  • Use of leucine-zipper protein for diagnosis or treatment of fatty liver
    Patent number: 10746727
    Abstract: The present invention relates to a use of leucine-zipper protein for diagnosis or treatment of fatty liver. According to the present invention, it could be confirmed that a particular fragment present at the leucine-zipper protein, especially, the N-terminal region thereof, plays an important role in the lipid metabolism in liver tissue by regulating transcriptional activity of Apolipoprotein A4, and therefore, the protein of the present invention or a fragment thereof can be utilized as a target for diagnosis, prevention, or treatment of fatty liver.
    Type: Grant
    Filed: November 20, 2017
    Date of Patent: August 18, 2020
    Assignee: Korea University Research and Business Foundation
    Inventors: Jesang Ko, Min-Soo Kang
  • Compositions and methods for inhibiting expression of CD274/PD-L1 gene
    Patent number: 10745704
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the CD274/PD-L1 gene, and methods of using such dsRNA compositions to inhibit expression of CD274/PD-L1.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: August 18, 2020
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Antonin DeFougerolles, Tatiana Novobrantseva, Brian Bettencourt